$SER Income Statement | Understand Stock

$SER

$1.67 -$0.04 (2.34%) Close

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2025 12 months to Dec 31, 2025	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021
Cost of sales
Gross profit
OPERATING EXPENSES
Research and development
General and administrative
Total operating expenses
Gain on deconsolidation of LifeMap Sciences (Note 3)
Gain on disposition of fixed assets
Loss from operations
OTHER INCOME, NET
Interest expense, net
Interest expense
Fair value inception adjustment on convertible promissory note
Change in fair value of convertible promissory notes
Change in fair value of warrants liabilities
Gain on warrants expiration
Other income, net
Total other income, net
NET LOSS FROM CONTINUING OPERATIONS
NET LOSS FROM DISCONTINUED OPERATIONS (Note 3)
Loss before income taxes
Provision for income taxes
Net loss
Net loss attributable to noncontrolling interest from discontinued operations
Net loss attributable to noncontrolling interest
Discontinued operations
BASIC AND DILUTED
Continuing operations
NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, BASIC
NET LOSS ATTRIBUTABLE TO SERINA THERAPEUTICS, INC. COMMON STOCKHOLDERS, DILUTED
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, BASIC (in usd per share)
NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDER, DILUTED (in usd per share)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, BASIC (in shares)
Loss from continuing operations
Loss from discontinued operations
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING, DILUTED (in shares)

Comments